Last reviewed · How we verify
Mycophénolate Mofétil
Mycophénolate Mofétil is a Inosine monophosphate dehydrogenase (IMPDH) inhibitor Small molecule drug developed by University Hospital, Limoges. It is currently FDA-approved for Prevention of organ transplant rejection (renal, cardiac, hepatic), Active lupus nephritis, Autoimmune conditions requiring immunosuppression.
Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent immune rejection.
Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent immune rejection. Used for Prevention of acute organ rejection in patients receiving allogeneic renal, cardiac, or hepatic transplants, Treatment of active lupus nephritis, Treatment of autoimmune conditions including rheumatoid arthritis and other systemic autoimmune diseases.
At a glance
| Generic name | Mycophénolate Mofétil |
|---|---|
| Sponsor | University Hospital, Limoges |
| Drug class | Inosine monophosphate dehydrogenase (IMPDH) inhibitor |
| Target | IMPDH type II |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
MMF is a prodrug that is rapidly hydrolyzed to mycophenolic acid (MPA), which preferentially inhibits IMPDH type II, the predominant isoform in activated lymphocytes. This blocks guanosine nucleotide synthesis required for lymphocyte DNA replication, thereby reducing T and B cell proliferation without affecting other cell types as severely. It is used as an immunosuppressant to prevent organ transplant rejection and treat autoimmune conditions.
Approved indications
- Prevention of organ transplant rejection (renal, cardiac, hepatic)
- Active lupus nephritis
- Autoimmune conditions requiring immunosuppression
Common side effects
- Gastrointestinal disturbances (diarrhea, nausea, vomiting, abdominal pain)
- Leukopenia
- Anemia
- Infection
- Headache
- Tremor
- Hypertension
Key clinical trials
- Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure (PHASE4)
- Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors (PHASE4)
- Benefit of Immunoprophylaxis on Fibrosis to Reduce Viral Load After Liver Transplantation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mycophénolate Mofétil CI brief — competitive landscape report
- Mycophénolate Mofétil updates RSS · CI watch RSS
- University Hospital, Limoges portfolio CI
Frequently asked questions about Mycophénolate Mofétil
What is Mycophénolate Mofétil?
How does Mycophénolate Mofétil work?
What is Mycophénolate Mofétil used for?
Who makes Mycophénolate Mofétil?
What drug class is Mycophénolate Mofétil in?
What development phase is Mycophénolate Mofétil in?
What are the side effects of Mycophénolate Mofétil?
What does Mycophénolate Mofétil target?
Related
- Drug class: All Inosine monophosphate dehydrogenase (IMPDH) inhibitor drugs
- Target: All drugs targeting IMPDH type II
- Manufacturer: University Hospital, Limoges — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of organ transplant rejection (renal, cardiac, hepatic)
- Indication: Drugs for Active lupus nephritis
- Indication: Drugs for Autoimmune conditions requiring immunosuppression
- Compare: Mycophénolate Mofétil vs similar drugs
- Pricing: Mycophénolate Mofétil cost, discount & access